{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:38:05Z","timestamp":1791441485028,"version":"4.3.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40264-026-01663-9","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:38:04Z","timestamp":1773833884000},"page":"985-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Liver Safety of the Dual Neurokinin-1\/-3 Receptor Antagonist Elinzanetant"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6686-3744","authenticated-orcid":false,"given":"James H.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1565-0757","authenticated-orcid":false,"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0892-3489","authenticated-orcid":false,"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-2454","authenticated-orcid":false,"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7495-518X","authenticated-orcid":false,"given":"Richard A.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Trajanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-8015","authenticated-orcid":false,"given":"Esther","family":"Groettrup-Wolfers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lineke","family":"Zuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"8","key":"1663_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/gme.0000000000001793","volume":"28","author":"RE Nappi","year":"2021","unstructured":"Nappi RE, Kroll R, Siddiqui E, Stoykova B, Rea C, Gemmen E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28(8):875\u201382. https:\/\/doi.org\/10.1097\/gme.0000000000001793.","journal-title":"Menopause"},{"issue":"4","key":"1663_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3949\/ccjm.91a.23067","volume":"91","author":"TK Iyer","year":"2024","unstructured":"Iyer TK, Fiffick AN, Batur P. Nonhormone therapies for vasomotor symptom management. Cleve Clin J Med. 2024;91(4):237\u201344. https:\/\/doi.org\/10.3949\/ccjm.91a.23067.","journal-title":"Cleve Clin J Med"},{"issue":"10430","key":"1663_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/s0140-6736(23)02802-7","volume":"403","author":"M Hickey","year":"2024","unstructured":"Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Nakawala Chilowa K, et al. Managing menopause after cancer. Lancet. 2024;403(10430):984\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(23)02802-7.","journal-title":"Lancet"},{"issue":"3","key":"1663_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","volume":"34","author":"NE Rance","year":"2013","unstructured":"Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013;34(3):211\u201327. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.003.","journal-title":"Front Neuroendocrinol"},{"issue":"5","key":"1663_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14051438","volume":"14","author":"B Meczekalski","year":"2025","unstructured":"Meczekalski B, Kostrzak A, Unogu C, Bochynska S, Maciejewska-Jeske M, Bala G, et al. A new hope for woman with vasomotor symptoms: neurokinin B antagonists. J Clin Med. 2025;14(5):1438. https:\/\/doi.org\/10.3390\/jcm14051438.","journal-title":"J Clin Med"},{"issue":"8","key":"1663_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa2415566","volume":"393","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med. 2025;393(8):753\u201363. https:\/\/doi.org\/10.1056\/NEJMoa2415566.","journal-title":"N Engl J Med"},{"issue":"16","key":"1663_CR7","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jama.2024.14618","volume":"332","author":"JV Pinkerton","year":"2024","unstructured":"Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343\u201354. https:\/\/doi.org\/10.1001\/jama.2024.14618.","journal-title":"JAMA"},{"issue":"11","key":"1663_CR8","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jamainternmed.2025.4421","volume":"185","author":"N Panay","year":"2025","unstructured":"Panay N, Joffe H, Maki PM, Nappi RE, Pinkerton JV, Simon JA, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial. JAMA Intern Med. 2025;185(11):1319\u201327. https:\/\/doi.org\/10.1001\/jamainternmed.2025.4421.","journal-title":"JAMA Intern Med"},{"key":"1663_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-015-0053-y","volume":"7","author":"R Liu","year":"2015","unstructured":"Liu R, Yu X, Wallqvist A. Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform. 2015;7:4. https:\/\/doi.org\/10.1186\/s13321-015-0053-y.","journal-title":"J Cheminform"},{"key":"1663_CR10","unstructured":"LiverTox: clinical and research information on drug-induced liver injury. 10 Jul 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/. Accessed 29 Aug 2025."},{"issue":"4","key":"1663_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today. 2016;21(4):648\u201353. https:\/\/doi.org\/10.1016\/j.drudis.2016.02.015.","journal-title":"Drug Discov Today"},{"issue":"9","key":"1663_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1021\/tx200168d","volume":"24","author":"AF Stepan","year":"2011","unstructured":"Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, et al. Structural alert\/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol. 2011;24(9):1345\u2013410. https:\/\/doi.org\/10.1021\/tx200168d.","journal-title":"Chem Res Toxicol"},{"key":"1663_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108291","volume":"157","author":"A Nuthi","year":"2025","unstructured":"Nuthi A, Mishra G, Dixit VA. Carbene reactive metabolite explains the hepatotoxicity of the hot flashes drug fezolinetant: a DFT investigation. Bioorg Chem. 2025;157:108291. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108291.","journal-title":"Bioorg Chem"},{"issue":"1","key":"1663_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s13318-024-00930-3","volume":"50","author":"SI Schulz","year":"2025","unstructured":"Schulz SI, Schultze-Mosgau MH, Engelen A, Singh N, Pawsey S, Francke K, et al. Mass balance recovery, absorption, metabolism, and excretion of elinzanetant in healthy humanvolunteers and in vitro biotransformation. Eur J Drug Metab Pharmacokinet. 2025;50(1):91\u2013103. https:\/\/doi.org\/10.1007\/s13318-024-00930-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1663_CR15","unstructured":"The human protein atlas. Version 24.0. 22 Oct 2024. Available from: https:\/\/www.proteinatlas.org. Accessed 16 Jun 2025."},{"issue":"6220","key":"1663_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. tissue-based map of the human proteome. Science. 2015;347(6220):1260419. https:\/\/doi.org\/10.1126\/science.1260419.","journal-title":"Science"},{"key":"1663_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan2507","author":"M Uhlen","year":"2017","unstructured":"Uhlen M, Zhang C, Lee S, Sj\u00f6stedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352):eaan2507. https:\/\/doi.org\/10.1126\/science.aan2507.","journal-title":"Science"},{"key":"1663_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3321","author":"PJ Thul","year":"2017","unstructured":"Thul PJ, \u00c5kesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, et al. A subcellular map of the human proteome. Science. 2017;356(6340):eaal3321.\u00a0https:\/\/doi.org\/10.1126\/science.aal3321.","journal-title":"Science"},{"key":"1663_CR19","unstructured":"US Food and Drug Administration. FDA safety communication. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. 2024. Available from: https:\/\/www.fda.gov\/media\/181764\/download?attachment. Accessed 14 Aug 2025."},{"key":"1663_CR20","doi-asserted-by":"publisher","unstructured":"Safety update: EMA and FDA warn of liver problems with \u25bcfezolinetant. Drug Ther Bull. 2025;63(3):36. https:\/\/doi.org\/10.1136\/dtb.2024.000070.","DOI":"10.1136\/dtb.2024.000070"},{"issue":"10081","key":"1663_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/s0140-6736(17)30823-1","volume":"389","author":"JK Prague","year":"2017","unstructured":"Prague JK, Roberts RE, Comninos AN, Clarke S, Jayasena CN, Nash Z, et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10081):1809\u201320. https:\/\/doi.org\/10.1016\/s0140-6736(17)30823-1.","journal-title":"Lancet"},{"key":"1663_CR22","unstructured":"Astellas Pharma US I. VEOZAH\u00ae prescribing information (US). FDA prescribing information for VEOZAH\u00ae (fezolinetant) tablets, for oral use. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216578s003lbl.pdf. Accessed 6 Jun 2025."},{"issue":"6","key":"1663_CR23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"EASL clinical practice guidelines","year":"2019","unstructured":"EASL clinical practice guidelines. drug-induced liver injury. J Hepatol. 2019;70(6):1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"key":"1663_CR24","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Drug-induced liver injury (DILI): current status and future directions for drug development and the post-marketing setting. A consensus by a CIOMS Working Group. 2020. Available from: https:\/\/cioms.ch\/wp-content\/uploads\/2020\/06\/CIOMS_DILI_Web_16Jun2020.pdf. Accessed 18 Jul 2025."},{"key":"1663_CR25","unstructured":"FDA. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation. Accessed 16 Jun 2025."},{"issue":"5","key":"1663_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/gme.0000000000001500","volume":"27","author":"M Trower","year":"2020","unstructured":"Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. Menopause. 2020;27(5):498\u2013505. https:\/\/doi.org\/10.1097\/gme.0000000000001500.","journal-title":"Menopause"},{"issue":"3","key":"1663_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/gme.0000000000002138","volume":"30","author":"JA Simon","year":"2023","unstructured":"Simon JA, Anderson RA, Ballantyne E, Bolognese J, Caetano C, Joffe H, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239\u201346. https:\/\/doi.org\/10.1097\/gme.0000000000002138.","journal-title":"Menopause"},{"issue":"7","key":"1663_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70282","volume":"18","author":"K Francke","year":"2025","unstructured":"Francke K, Klein S, Burke J, Schultze-Mosgau MH, Kay G. The effects of elinzanetant on simulated driving performance in healthy women: a randomized phase I study. Clin Transl Sci. 2025;18(7):e70282. https:\/\/doi.org\/10.1111\/cts.70282.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"1663_CR29","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1663_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55\u201368. https:\/\/doi.org\/10.2165\/00002018-200932010-00005.","journal-title":"Drug Saf"},{"issue":"4","key":"1663_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/2168479016628574","volume":"50","author":"B Crowe","year":"2016","unstructured":"Crowe B, Chuang-Stein C, Lettis S, Brueckner A. Reporting adverse drug reactions in product labels. Ther Innov Regul Sci. 2016;50(4):455\u201363. https:\/\/doi.org\/10.1177\/2168479016628574.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"1663_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1053\/j.gastro.2014.03.050","volume":"147","author":"M Robles-Diaz","year":"2014","unstructured":"Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-C\u00e1liz I, Gonz\u00e1lez-Jimenez A, et al. Use of Hy\u2019s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014;147(1):109-118.e105. https:\/\/doi.org\/10.1053\/j.gastro.2014.03.050.","journal-title":"Gastroenterology"},{"issue":"7","key":"1663_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/17425255.2017.1341489","volume":"13","author":"RJ Weaver","year":"2017","unstructured":"Weaver RJ, Betts C, Blomme EAG, Gerets HHJ, Gjervig Jensen K, Hewitt PG, et al. Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. Expert Opin Drug Metab Toxicol. 2017;13(7):767\u201382. https:\/\/doi.org\/10.1080\/17425255.2017.1341489.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"1663_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/10937404.2023.2261848","volume":"26","author":"R Allison","year":"2023","unstructured":"Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug induced liver injury - a 2023 update. J Toxicol Environ Health B Crit Rev. 2023;26(8):442\u201367. https:\/\/doi.org\/10.1080\/10937404.2023.2261848.","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"1","key":"1663_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/livers4010008","volume":"4","author":"PA Patel-Rodrigues","year":"2024","unstructured":"Patel-Rodrigues PA, Cundra L, Alhaqqan D, Gildea DT, Woo SM, Lewis JH. Herbal- and dietary-supplement-induced liver injury: a review of the recent literature. Livers. 2024;4(1):94\u2013118. https:\/\/doi.org\/10.3390\/livers4010008.","journal-title":"Livers"},{"issue":"5","key":"1663_CR36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40264-025-01514-z","volume":"48","author":"H Singh","year":"2025","unstructured":"Singh H, Kunkle BF, Troia AR, Suvarnakar AM, Waterman AC, Khin Y, et al. Drug induced liver injury: highlights and controversies in the 2023 literature. Drug Saf. 2025;48(5):455\u201388. https:\/\/doi.org\/10.1007\/s40264-025-01514-z.","journal-title":"Drug Saf"},{"key":"1663_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2017.09.013","volume":"77","author":"J Vidaurre","year":"2017","unstructured":"Vidaurre J, Gedela S, Yarosz S. Antiepileptic drugs and liver disease. Pediatr Neurol. 2017;77:23\u201336. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2017.09.013.","journal-title":"Pediatr Neurol"},{"key":"1663_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/B978-0-12-387817-5.00027-3","volume-title":"Drug-induced liver disease","author":"S Verma","year":"2013","unstructured":"Verma S, Kaplowitz N. Hepatotoxicity of antitubercular drugs. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Boston: Academic Press; 2013. p. 483\u2013504.","edition":"3"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/B978-0-12-387817-5.00029-7","volume-title":"Drug-induced liver disease","author":"D Halegoua-De Marzio","year":"2013","unstructured":"Halegoua-De Marzio D, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic drugs. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Boston: Academic Press; 2013. p. 519\u201340.","edition":"3"}],"updated-by":[{"DOI":"10.1007\/s40264-026-01675-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000}}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01663-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01663-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:19:30Z","timestamp":1783657170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01663-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01663-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been corrected. The text 'does share' should have read 'does not share' under the 'Introduction' section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40264-026-01675-5","URL":"https:\/\/doi.org\/10.1007\/s40264-026-01675-5","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were sponsored by Bayer. The sponsor was involved in data analysis, validation, and manuscript development for the analysis presented in this publication and provided resources and administration support for the project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James H. Lewis is a member of the elinzanetant LSMB and paid consultant to Bayer; also a paid consultant to Astellas. James H. Lewis is an editorial board member of\n                      Drug Safety\n                      . James H. Lewis was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. Ra\u00fal J. Andrade is a member of the elinzanetant LSMB and a paid consultant to Bayer; also a paid consultant to Abbott, Boehringer Ingelheim, ENYO, GSK, Inventiva, Novartis, Novo-Nordisk, Roche, Ryvu Therapeutics, and Sanofi. Dominique Larrey is a member of the elinzanetant LSMB and a paid consultant to Bayer; also a paid consultant to Alentis, Akero, Alexion, Calliditas, Chiesi, Debiopharm, Freeline, Insilico, Inventiva, Merck, Pfizer, Ryvu, Sanofi, UCB, and Voiant. Yves Horsmans is a member of the elinzanetant DSMB and a paid consultant to Bayer; also a paid consultant to Debiopharm, Pharvaris, Chiesi, Jazz Pharmaceuticals, Novartis, and Johnson & Johnson. Richard A. Anderson is a member of the elinzanetant DSMB and a paid consultant to Bayer; also a paid consultant to Merck and Ferring. Lineke Zuurman is an employee of Bayer CC AG, Switzerland. Mila Trajanovic is an employee of Bayer US LLC, Whippany, NJ, USA. Esther Groettrup-Wolfers is an employee of Bayer AG, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All the elinzanetant studies referenced were conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. Institutional review board and ethics committee approval were obtained for all study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Availability of the data underlying this publication will be determined according to Bayer\u2019s commitment to the EFPIA\/PhRMA \u201cPrinciples for responsible clinical trial data sharing.\u201d This pertains to scope, timepoint, and process of data access. As such, Bayer commits to sharing upon request from qualified scientific and medical researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the USA and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after 1 January 2014. Interested researchers can use\n                      \n                      to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal. Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the conceptualization and design of the analysis. Formal analysis was performed by Bayer and the Elinzanetant Liver Safety Monitoring Board (J.H.L., R.J.A., D.L.). Data curation was managed by L.Z., M.T., and E.G.W. The first draft was written by L.Z. and J.H.L. with medical writing support from Fourwave\n                      TM\n                      Medical Communications UK. All authors reviewed and edited drafts of the manuscript, and read and approved the final version of the manuscript for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}